RxDoctor Payments Data

Eric Mascellino, DPM

Primary Podiatric Medicine · Miami, FLNPI 1609438282

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.4% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Smith+Nephew at 28.8% of the total. Reporting peaked in 2023 at $483 and has fallen 74.7% since, to $122 in 2025.

$1,751in general payments, 2019–2025

Across 58 payments — averaging $30.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$504
  • Osteomed LLC$300
  • Paragon 28, Inc.$273
  • Aroa Biosurgery Incorporated$172
  • Integra Lifesciences Corporation$122
  • Stryker$64
  • plus $314 from 10 others

What the payments were for

  • Food & beverage$1,60091%
  • Education$1519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,751 in reported general payments places this provider in the 70th percentile of 68 primary podiatric medicine providers in Florida.

See all primary podiatric medicine providers in Florida

Medicare billing

Part B allowed, 2024
$100,189
Medicare patients
251
Services billed
1,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ammonium Lactate289$4,084
Ciclopirox105$2,681
Clotrimazole73$830
SsdSilver Sulfadiazine26$441
Ketoconazole12$313
Mupirocin39$244
Triamcinolone Acetonide19$240
Silver Sulfadiazine23$132

Paid to pharmacies, not to this prescriber.

Other primary podiatric medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →